Halozyme Therapeutics, Inc. ( HALO) - Stock Earnings
HALO Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q3 | 175.2 million USD | 354.3 million USD |
| 2025Q4 | -141.6 million USD | 451.8 million USD |
| 2026Q1 | 150.0 million USD | 376.7 million USD |
| 2026Q2 Est. | — | — |
| 2026Q3 Est. | — | — |
| 2026Q4 Est. | — | — |
HALO Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | 281.6 million USD | 829.3 million USD |
| 2024 | 444.1 million USD | 1.0 billion USD |
| 2025 | 316.9 million USD | 1.4 billion USD |
| 2026 Est. | — | — |
HALO
Price: $70.90
52 week price:
Payout Ratio Range:
Earnings Per Share: 2.85 USD
P/E Ratio: 23.55
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 402302
Ebitda: 127.5 millionMarket Capitalization: 8.5 billion